Zacks: Analysts Anticipate Entellus Medical, Inc. (ENTL) Will Announce Earnings of -$0.51 Per Share
Analysts expect that Entellus Medical, Inc. (NASDAQ:ENTL) will post ($0.51) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Entellus Medical’s earnings, with the lowest EPS estimate coming in at ($0.57) and the highest estimate coming in at ($0.47). Entellus Medical posted earnings of ($0.50) per share during the same quarter last year, which would indicate a negative year over year growth rate of 2%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 2nd.
According to Zacks, analysts expect that Entellus Medical will report full year earnings of ($1.62) per share for the current year, with EPS estimates ranging from ($1.77) to ($1.53). For the next year, analysts anticipate that the company will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.21) to ($0.76). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Entellus Medical.
Entellus Medical (NASDAQ:ENTL) last posted its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03). The firm had revenue of $22.10 million for the quarter, compared to analysts’ expectations of $21.87 million. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.27) earnings per share.
ENTL has been the subject of several research reports. Piper Jaffray Companies reiterated a “buy” rating and issued a $21.00 price target on shares of Entellus Medical in a research report on Tuesday, August 22nd. BidaskClub upgraded shares of Entellus Medical from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. Finally, Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $21.71.
In other Entellus Medical news, VP Stephen R. Paidosh sold 25,000 shares of the business’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $17.54, for a total value of $438,500.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Timothy B. Petrick sold 2,000 shares of the business’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $18.00, for a total transaction of $36,000.00. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in ENTL. Bank of America Corp DE increased its stake in Entellus Medical by 53.8% in the 1st quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock valued at $102,000 after buying an additional 2,594 shares during the period. Nationwide Fund Advisors increased its stake in Entellus Medical by 61.7% in the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after buying an additional 2,635 shares during the period. First Mercantile Trust Co. increased its stake in Entellus Medical by 45.3% in the 2nd quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock valued at $136,000 after buying an additional 2,557 shares during the period. Parametric Portfolio Associates LLC increased its stake in Entellus Medical by 5.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after buying an additional 573 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in Entellus Medical by 61.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock valued at $196,000 after buying an additional 4,533 shares during the period. 70.41% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/zacks-analysts-anticipate-entellus-medical-inc-entl-will-announce-earnings-of-0-51-per-share/1600656.html.
Shares of Entellus Medical (NASDAQ:ENTL) opened at 18.46 on Friday. The stock’s 50 day moving average is $17.37 and its 200-day moving average is $17.37. Entellus Medical has a 12-month low of $12.31 and a 12-month high of $22.57. The stock’s market capitalization is $468.35 million.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.